Site-specific trastuzumab Fab-DM1 via butelase-1 with ABD fusion for potent HER2-positive tumor control. - Han Y; Guo Q; Cao H; Qin T; Zhang X; Dong Q; Huang Y; Mao Y; Wang Z; Liu Q; Liu Y; Zhang S (Medical oncology (Northwood, London, England), 2026)